Full-Time

Director Medical Affairs Oncology

Strategic Evidence & Collaborations

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$221k - $314.6k/yr

+ Discretionary annual bonus + Discretionary stock-based long-term incentives

Company Historically Provides H1B Sponsorship

Remote in USA

Hybrid

Remote role requiring headquarters travel for specific quarterly meetings and more than 50% domestic and international travel.

Bachelor's, Master's, PharmD, PhD, MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
FDA Regulations

Get referred to Gilead Sciences

See people who can refer or advise you

Requirements
  • An advanced medical or scientific degree, such as a PhD, MD, or PharmD, and at least 8 years of experience in Medical Affairs or a similar role outside the biotech or pharmaceutical industry; alternatively, an MA/MS and at least 10 years of such experience; or a BA/BS and at least 12 years of such experience.
  • At least 10 years of experience in Medical Affairs or a similar role outside the biotech or pharmaceutical industry is preferred.
  • Experience specific to oncology is preferred.
  • Ability to think strategically and translate strategy into an actionable work plan.
  • Strong written, verbal, interpersonal, relationship-building, negotiating, and communication skills.
  • Strong organizational skills to support project planning across multiple activities and to anticipate and prioritize workload.
  • Strong teamwork skills.
  • Attention to detail and ability to meet timelines in a fast-paced environment.
  • Strong analytical and problem-solving skills, including the ability to identify and understand complex issues and problems and query key findings from study data and publications.
  • Knowledge of FDA regulations, International Council for Harmonisation guidelines, and Good Clinical Practice requirements governing clinical trials and related Medical Affairs activities is preferred.
  • Ability to work with a high level of autonomy and independence.
Responsibilities
  • Co-develop the US Medical Affairs strategy for US Medical Affairs congress plans in collaboration with the Congress Center of Excellence, US Medical Affairs Strategy team, and field-based medical teams.
  • Represent and consider the US healthcare environment with internal and external stakeholders involved in cancer therapies across approved and pipeline molecules and indications.
  • Establish and execute an overarching US evidence-generation strategy across various tumor types, including collaboration with cooperative groups, the National Cancer Institute Clinical Trials Network, and other key organizations.
  • Provide internal and external input into US and Global Medical Affairs Strategic Plans, particularly the Integrated Strategic Plan, and contribute to the medical Plan of Action.
  • Demonstrate subject-matter expertise in the full antibody-drug conjugate portfolio, Gilead clinical trials and their clinical use, and competitive products.
  • Collaborate as a thought partner and significant contributor to the Community Cancer Collective team.
  • Develop strategies and implementation plans addressing education, research, Medical Affairs insights, and data-generation needs in the US.
  • Prepare presentation materials and present scientific data at internal meetings and external advisory boards.
  • Support global and regional congress strategic planning and tactical execution with the SEC lead and Congress Center of Excellence.
  • Lead or support US Medical Affairs medical efforts and strategic planning for US-based oncology societies.
  • Provide medical and scientific leadership and support at key scientific meetings with US healthcare professionals and patients.
  • Serve as an information resource to Gilead colleagues, including US Medical Science Liaisons, for medical education activities, grants, and investigator-sponsored or collaborative studies.
  • Collaborate with the Medical Affairs Research team and Clinical Research and Development on collaboration research.
  • Occasionally deliver timely, accurate, and succinct fair-balanced clinical and scientific presentations to healthcare professionals in compliance with promotional and regulatory requirements.
  • Occasionally participate in editorial review of scientific content for strategic alignment and accuracy.
  • Support development of the disease-specific publication strategy.
  • Critically review global collaboration research, Phase 3b, and Phase 4 study proposals generated in the US.
  • Review abstracts and manuscripts resulting from US collaboration research.
  • Communicate Gilead’s commitment to scientific excellence through research and education.
  • Provide strategic input to the Global Medical Affairs Plan.
  • Collaborate compliantly with colleagues in other functional areas throughout Gilead.
  • Perform other assigned activities supporting US Medical Affairs strategy development and tactical execution.
Desired Qualifications
  • Experience developing effective abstracts, manuscripts, posters, and slides and presenting at scientific meetings.
  • Thorough knowledge of FDA regulations, International Council for Harmonisation guidelines, and Good Clinical Practice requirements governing clinical trials and related Medical Affairs activities.

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 product sales excluding Veklury rose 10%, and guidance increased to $30.4 billion.
  • Yeztugo reached a $1 billion annual run rate with strong patient retention by August 2026.
  • Anito-cel’s FDA PDUFA date is December 23, 2026, creating a near-term oncology catalyst.

What critics are saying

  • HIV still generated nearly three-quarters of quarterly product sales in Q2 2026.
  • Cell therapy sales fell 14% in Q2 2026, showing Kite faces harsh competition.
  • Arcellx integration cut 192 jobs, signaling execution risk and post-deal disruption through 2027.

What makes Gilead Sciences unique

  • Gilead owns HIV leadership with Biktarvy, Descovy, and Yeztugo driving 2026 growth.
  • The August 2026 Arcellx acquisition strengthens Gilead’s CAR-T position for anito-cel.
  • Gilead’s California Supreme Court victory protects its innovation model across future drug portfolios.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 24th, 2026
Gilead posts $11B loss on pipeline acquisitions despite 10% product sales growth

Gilead Sciences reported strong commercial performance in Q2 2026, with product sales excluding Veklury rising 10% to $7.6 billion. HIV revenue grew 12% to $5.7 billion, led by Biktarvy at $3.8 billion and Descovy at $967 million. Despite this growth, the company posted one of its largest quarterly losses due to over $11 billion in acquired research and development expenses. These acquisitions included Arcellx, which gives Gilead full control of anito-cel, a CAR-T treatment for multiple myeloma pending FDA approval by December 2026. The company raised its 2026 product-sales guidance to $30.1–$30.4 billion. Gilead also reported encouraging progress beyond HIV, with liver-disease revenue up 10% and Trodelvy breast-cancer treatment sales rising 26% to $457 million.

Yahoo Finance
Aug 23rd, 2026
Gilead's HIV sales surge 12% to $5.7B, but franchise accounts for 75% of total revenue

Gilead Sciences reported strong fiscal Q2 2026 results, with total revenue rising 10% year-over-year to approximately $7.8 billion. The growth was primarily driven by its HIV franchise, including Biktarvy and newly launched Yeztugo. HIV product sales rose 12% to $5.7 billion, representing nearly three-quarters of quarterly product sales. Descovy sales increased 48% to $967 million, whilst Biktarvy sales grew 7% to $3.8 billion. Yeztugo generated $232 million, up substantially from $15 million in the prior-year period. The company's liver disease portfolio sales rose 10% to $877 million. However, cell therapy sales declined 14% to $417 million, reflecting competitive pressure. Gilead recorded an $11.2 billion quarterly loss due to acquired research and development expenses, including $7.0 billion for the Arcellx acquisition.

Ticker Report
Aug 18th, 2026
MidFirst Bank Makes New $810,000 Investment in Gilead Sciences, Inc. $GILD

MidFirst Bank acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 6,414 shares of the biopharmaceutical company’s stock, valued at approximately $810,000. A number of other hedge funds and other institutional investors […]

Yahoo Finance
Aug 16th, 2026
Gilead Sciences down 11.3% in six months as revenue growth disappoints at 2.7% CAGR

Gilead Sciences' shares have fallen 11.3% to $137.77 over the past six months, contrasting with the S&P 500's 13.1% gain. The biopharmaceutical company has shown disappointing long-term performance, with revenue growing at just 2.7% annually over five years. The company's profitability metrics have deteriorated significantly. Its adjusted operating margin decreased by 34.2 percentage points over the past five years, landing at 9.7% for the trailing 12 months. Earnings per share declined by 15.4% annually during the same period, indicating reduced profitability as the company expanded. Despite trading at a relatively fair valuation of 14.9× forward price-to-earnings ratio, analysts suggest limited upside potential compared to downside risk.

Yahoo Finance
Aug 13th, 2026
Gilead Sciences beats Q2 estimates with $7.8B revenue as PrEP sales top $1B for first time

Gilead Sciences reported strong Q2 results, with revenue of $7.80 billion, beating analyst estimates of $7.35 billion. The 10.2% year-on-year growth was driven by its HIV franchise, particularly Biktarvy and the PrEP segment, alongside advances in oncology and liver disease treatments. CEO Daniel O'Day highlighted that quarterly PrEP sales doubled year-on-year, exceeding $1 billion for the first time. New product launches, including Trodelvy in breast cancer and Livdelzi in liver disease, contributed to the results. The company raised its full-year revenue guidance to $30.25 billion at the midpoint and increased adjusted EPS guidance by 44.1%. During the earnings call, analysts questioned management about prescription trends, product strategies, revenue diversification, regulatory interactions, and the impact of US insurance changes on Biktarvy's growth.